Immunotherapy Treatment for Triple Negative Breast Cancer

Immunotherapy Treatment for Triple Negative Breast Cancer

Triple-negative breast cancer (TNBC) is considered one of the highest-risk subtypes of breast cancer and has dismal prognosis. Local recurrence rate after standard therapy in the early breast cancer setting can be upwards to 72% in 5 years, and in the metastatic setting, the 5-year overall survival...

Full description

Saved in:
Bibliographic Details
Main Authors: Elizabeth R. Berger (Author), Tristen Park (Author), Angeleke Saridakis (Author), Mehra Golshan (Author), Rachel A. Greenup (Author), Nita Ahuja (Author)
Format: Book
Published: MDPI AG, 2021-08-01T00:00:00Z.
Subjects:
article
Online Access:Connect to this object online.
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

Connect to this object online.

3rd Floor Main Library

Holdings details from 3rd Floor Main Library
Call Number: A1234.567
Copy 1 Available

Similar Items